|
| Sample group | Category | Term | Count | value | Genes |
|
| 80 | CC | Extracellular exosome | 25 | 0.000123351 | GALNT3; LPL; HYAL1; ACTC1; HIST1H2AE; QDPR; SELENBP1; NPR3; TMEM27; EMILIN1; LYVE1; KRT19; TEX14; PTGDS; VAMP8; DMKN; AOX1; GDF15; CFD; SPON2; NQO1; DEFB1; IGFBP3; DCXR; HIST1H4H |
| 80 | CC | Extracellular space | 16 | 0.000207983 | IBSP; HYAL1; LPL; ACTC1; CYTL1; SELENBP1; PTHLH; TNFAIP6; PTGDS; SCGB1D2; TFPI; SPON2; CFD; GDF15; IGFBP3; DEFB1 |
| 49 | MF | Virus receptor activity | 4 | 0.00065 | HYAL1; LDLR; CD80; EFNB2 |
| 80 | BP | Cellular response to zinc ion | 3 | 0.002491898 | MT1M; MT1G; MT1F |
| 80 | BP | Negative regulation of growth | 3 | 0.002491898 | MT1M; MT1G; MT1F |
| 80 | MF | Virus receptor activity | 4 | 0.002592014 | HYAL1; LDLR; CD80; EFNB2 |
| 80 | CC | Extracellular region | 15 | 0.003781513 | IBSP; LPL; EMILIN1; PTHLH; PTGDS; NPTX2; DMKN; TFPI; TREM1; CFD; GDF15; IGFBP3; DEFB1; HIST1H4H; COL10A1 |
| 80 | BP | Viral entry into host cell | 4 | 0.003840079 | LDLR; CD80; VAMP8; EFNB2 |
| 80 | BP | Cell adhesion | 7 | 0.009200697 | IBSP; TNFAIP6; LYVE1; CYP1B1; EFNB2; SPON2; EMILIN1 |
| 49 | MF | Hyaluronan synthase activity | 2 | 0.009680585 | HYAL1; HAS2 |
| 80 | MF | Hyaluronan synthase activity | 2 | 0.015548781 | HYAL1; HAS2 |
| 49 | BP | Viral entry into host cell | 3 | 0.017061685 | LDLR; CD80; EFNB2 |
| 49 | BP | Hyaluronan biosynthetic process | 2 | 0.017380591 | HYAL1; HAS2 |
| 80 | BP | Cell-cell signaling | 5 | 0.017725805 | PTHLH; TNFAIP6; CD80; EFNB2; GDF15 |
| 80 | TH | Neral absorption | 3 | 0.019704118 | MT1M; MT1G; MT1F |
| 49 | MF | Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence spec | 3 | 0.022287725 | LMO2; GATA6; FOXF2 |
| 80 | BP | Response to estrogen | 3 | 0.026997667 | KRT19; CCND1; GATA6 |
| 80 | BP | Hyaluronan biosynthetic process | 2 | 0.027195604 | HYAL1; HAS2 |
| 49 | BP | Cell adhesion | 5 | 0.027213497 | IBSP; LYVE1; CYP1B1; EFNB2; SPON2 |
| 80 | MF | Transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding | 3 | 0.027502988 | T; GATA6; FOXF2 |
| 49 | BP | Response to ethanol | 3 | 0.028347603 | ACTC1; CCND1; NQO1 |
| 49 | BP | Retinal metabolic process | 2 | 0.029614391 | CYP1B1; SDR16C5 |
| 49 | MF | Transcription factor binding | 4 | 0.031391824 | HYAL1; CCND1; GATA6; FOXF2 |
| 80 | BP | Cellular response to interleukin-1 | 3 | 0.031774689 | HYAL1; TFPI; HAS2 |
| 49 | BP | Positive regulation of urine volume | 2 | 0.032043246 | HAS2; NPR3 |
| 49 | BP | Nitric oxide biosynthetic process | 2 | 0.032043246 | CYP1B1; NQO1 |
| 49 | BP | Positive regulation of angiogenesis | 3 | 0.033505165 | HYAL1; CYP1B1; GATA6 |
| 49 | BP | Positive regulation of transcription from RNA polymerase II promoter | 7 | 0.033985253 | DLX3; LMO2; GATA6; EBF1; FOXF2; CYTL1; ZEB2 |
| 49 | BP | Hyaluronan catabolic process | 2 | 0.036883166 | HYAL1; LYVE1 |
| 49 | BP | Response to drug | 4 | 0.040149506 | LPL; ACTC1; CCND1; GATA6 |
| 80 | CC | Transcription factor complex | 4 | 0.040958701 | LMO2; GATA6; FOXF2; PDLIM1 |
| 80 | BP | Extracellular matrix organization | 4 | 0.041931952 | IBSP; FOXF2; EMILIN1; COL10A1 |
| 49 | BP | Cellular response to platelet-derived growth factor stimulus | 2 | 0.044098781 | HYAL1; HAS2 |
| 80 | BP | Retinal metabolic process | 2 | 0.046173764 | CYP1B1; SDR16C5 |
| 80 | BP | Response to estradiol | 3 | 0.049819454 | CCND1; TFPI; NQO1 |
| 80 | BP | Nitric oxide biosynthetic process | 2 | 0.049925405 | CYP1B1; NQO1 |
| 80 | BP | Positive regulation of urine volume | 2 | 0.049925405 | HAS2; NPR3 |
|
